Shenzhen Kangtai Biological Products Co., Ltd. (SZSE: 300601)
Health Care · Biotechnology · CN
CN¥13.03
+2.68% today · -34.9% 1Y
Shenzhen Kangtai Biological Products Co., Ltd. (SZSE: 300601) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.16B and employs 1,957 people.
Over the last twelve months the share price has lost 34.9%, trading between 10.70 and 21.12.
Tweenvest scores Shenzhen Kangtai Biological Products Co., Ltd. across four factors: quality 65/100, value 45/100, growth 35/100, dividend 17/100. Its strongest factor is quality.
300601 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.16B
- Revenue (TTM)
- $375.99M
- P/E
- 164.55
- EPS
- 0.08
- Dividend yield
- 0.41%
- Beta (5Y)
- 0.62
- 52-week high
- CN¥21.12
- 52-week low
- CN¥10.70
- Avg volume (3M)
- —
- Shares outstanding
- 1.12B
- Employees
- 1,957
- Next earnings
- —
About Shenzhen Kangtai Biological Products Co., Ltd.
Established in 1992 and headquartered in Shenzhen, China, Shenzhen Kangtai Biological Products Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of a diverse array of human vaccines across the Chinese market. The company's extensive portfolio includes essential immunizations such as the SARS-COV-2 vaccine, recombinant hepatitis B vaccine, and various pneumococcal disease vaccines (including 13-valent conjugate and 23-valent polysaccharide types). Its offerings also encompass combined vaccines like diphtheria, tetanus, acellular pertussis, and haemophilus influenzae type b, in addition to specific haemophilus influenzae type b conjugate, measles and rubella live attenuated, rabies, and inactivated poliomyelitis vaccines. Internationally, the company has partnered with YTB and Yong Tai Berhad to develop and commercialize a Covid-19 inactivated vaccine specifically for Malaysia.
- ISIN
- CNE100002Q33
- Founded
- 1992
- Listed since
- Feb 8, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.95 | -1.81% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.